3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
4
Breast Neoplasms
3
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Triple Negative Breast Neoplasms
1
Toxemia
1
Stomach Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Primary Ovarian Insufficiency
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Myocarditis
1
Muscle Weakness
1
Melanoma
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Diabetes, Gestational
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Neuroendocrine
1
Carcinoma in Situ
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
ruxolitinib
13
Cyclophosphamide
5
Tacrolimus
4
Stem Cell Transplantation
4
Specimen Handling
4
fludarabine phosphate
3
Whole-Body Irradiation
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Cyclosporine
3
fludarabine
2
fedratinib
2
Sirolimus
2
Injections
2
Busulfan
2
Blood Component Removal
2
Biopsy
2
Azacitidine
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
veliparib
1
umbralisib
1
thymoglobulin
1
selinexor
1
reparixin
1
piperine
1
pevonedistat
1
pegylated granulocyte colony-stimulating factor
1
navitoclax
1
luspatercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
Positron-Emission Tomography
×
90 days
×
Clear all
No trials found.